A new class of drug may increase alertness without any of the jitteriness of over-stimulation, suggest the results of a small clinical trial released this week.

A compound dubbed CX717, a member of the new class called ampakines, significantly improved performance on tests of memory, attention, alertness, reaction time and problem solving in healthy men deprived of sleep.

The study was carried out by Julia Boyle at the Sleep Research Centre at the University of Surrey, UK, and her colleagues on behalf of Cortex Pharmaceuticals Inc., based in Irvine, California, US.

Doctors have found important new evidence to explain why mental function becomes less efficient with ageing. In the first study of its type in the world, a team at the University of Edinburgh found that worse mental function is linked with abnormally enlarged channels around blood vessels in the brain. The report, published in the Journal of Neurology, Neurosurgery and Psychiatry, will help doctors to better understand the causes of dementia.

Dementia and milder forms of loss of mental ability affects millions of older people every year, but the causes are unclear. Previous research using brain scanning has shown that brain shrinkage and changes in the brain's white matter 'wiring', are associated with mental function slowing down in old age. This research adds a new way in which damage to the brain may result in dementia and other mental loss in older people.

Ray Kurzweil has proposed a nanobiotechnology research program to replace the cell nucleus and ribosome machinery with a nanocomputer and nanobot to prevent diseases and aging and another program to create defensive technologies against rogue designer viruses.

Kurzweil presented the ideas in a keynote at the recent "Breakthrough Technologies for the World's Biggest Problems" conference on April 28, sponsored by the Arlington Institute.